Derm-Biome Pharmaceuticals develops topical therapies targeting inflammatory skin diseases, precancerous conditions, and non-melanoma skin cancers, utilizing advanced formulations to enhance safety and efficacy. The company addresses the limitations of current treatments, which often have inadequate effectiveness and significant side effects, by providing better compliance and improved patient outcomes.
Funding
$327.8K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current treatments for inflammatory skin diseases, precancerous conditions, and non-melanoma skin cancers often suffer from limited efficacy and significant side effects, leading to poor patient compliance and suboptimal outcomes. Topical steroids, a common treatment for inflammatory skin diseases like atopic dermatitis, can have unwanted side effects. Existing non-steroidal drugs frequently target only one or two pathways, resulting in reduced effectiveness.
Solution
Derm-Biome Pharmaceuticals develops topical therapies designed to address these limitations by providing safer and more effective treatments for a range of dermatological conditions. Their approach focuses on advanced formulations that target multiple pathways involved in skin diseases and aging. For example, DB-007-5, their compound for atopic dermatitis, inhibits a wide array of overactive pathways and has demonstrated significant inhibitory effects on both disease score and itch in preclinical studies. Similarly, their compound for precancerous lesions has shown promise in reducing the number and size of lesions and blocking the progression of squamous cell carcinoma in preclinical models. Their anti-aging compound, DB-007-4, inhibits pro-inflammatory cytokines and stimulates collagen synthesis, potentially improving skin appearance and slowing skin aging.
Target Audience
The primary target audience includes individuals suffering from inflammatory skin diseases such as atopic dermatitis, those with precancerous skin conditions like actinic keratosis, and individuals seeking anti-aging solutions.
Features
- DB-007-5: Topical treatment for atopic dermatitis targeting multiple inflammatory pathways, demonstrating significant reduction in disease score and itch in preclinical studies.
- Compound for Pre-Cancer/Skin Cancer: Topical application significantly reduces the number and size of precancerous lesions and blocks the progression of squamous cell carcinoma in preclinical models.
- DB-007-4: Topical treatment for anti-aging, inhibiting pro-inflammatory cytokines (IL-17A and IL-17E) and stimulating collagen synthesis.
- Focus on topical therapies to improve patient compliance and reduce systemic side effects.
- Development of treatments for acne and rosacea.